Search results
Results From The WOW.Com Content Network
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
A number of companies were expected to develop Ebola vaccines: GlaxoSmithKline, NewLink Genetics, Johnson & Johnson, and Bavarian Nordic. [82] Another company, Emergent BioSolutions, was a contestant for manufacturing new doses of ZMapp, [citation needed] a drug for Ebola virus disease treatment originally developed by Mapp Biopharmaceutical. [83]
The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...
cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID). [1]
During the 2018 Équateur province Ebola outbreak, a similar monoclonal antibody treatment, mAb114, was requested by the Democratic Republic of Congo (DRC) Ministry of Public Health. mAb114 was approved for compassionate use by the World Health Organization MEURI ethical protocol and at DRC ethics board. mAb114 was sent along with other ...
In fact, the nature of Ebola - which is spread by close contact with bodily fluids and blood - means that any modern hospital using standard, rigorous, infection-control measures should be able to ...
A stockpile of half-a-million Ebola vaccine doses was established by Gavi and other global health partners in 2019 for use in outbreaks of haemorrhagic fever, which has an average fatality rate of ...
The 2018 Équateur province Ebola outbreak occurred in the north-west of the Democratic Republic of the Congo (DRC) from May to July 2018. It was contained entirely within Équateur province, and was the first time that vaccination with the rVSV-ZEBOV Ebola vaccine had been attempted in the early stages of an Ebola outbreak, [6] with a total of 3,481 people vaccinated.